2833b2f4-e943-4570-96c2-a42c127cd1fa
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.600
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- IL6_JAK_STAT3_SIGNALING+0.500
- INFLAMMATORY_RESPONSE+0.500
- IL2_STAT5_SIGNALING+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- COMPLEMENT+0.300
- HEDGEHOG_SIGNALING+0.300
- KRAS_SIGNALING_UP+0.300
Top 10 suppressed
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.500
- MYC_TARGETS_V2-0.500
- MYC_TARGETS_V1-0.400
- DNA_REPAIR-0.300
- FATTY_ACID_METABOLISM-0.200
- MITOTIC_SPINDLE-0.200
- OXIDATIVE_PHOSPHORYLATION-0.100
- SPERMATOGENESIS-0.100
- UNFOLDED_PROTEIN_RESPONSE-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 74cffe84-dca8-4673-925a-9e0d6344832a | — | — | 0.902 |
| 2 | bd09bf00-3fb3-41fc-ae4d-4ac68a925a6b | — | — | 0.896 |
| 3 | BS_55JW3HFM | Ganglioglioma | — | 0.892 |
| 4 | 311f1988-e21e-4130-b944-2a34d7d46d28 | — | — | 0.889 |
| 5 | BS_KX6J8TRK | pilocytic astrocytoma | — | 0.889 |
| 6 | SRR5088825 | — | — | 0.883 |
| 7 | SJBT031351_D1.RNA-Seq | EPN | Supratentorial EPN | 0.881 |
| 8 | 20060029.TNBC | — | D | 0.875 |
| 9 | BS_PK18H7E7 | low-grade glioma | — | 0.874 |
| 10 | BS_52426AMF | low-grade glioma | — | 0.873 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |